We recently had the opportunity to watch a compelling documentary titled The Science of Inspiration, which chronicles the journeys of the twelve members of the inaugural...

In a recent study, Novo Nordisk's next-generation basal insulin degludec was found to cause less hypoglycemia than Lantus. In early May, Novo Nordisk announced the...

In 2007, Dr. Steven Nissen and Kathy Wolski of the Cleveland Clinic published an analysis on the cardiovascular risk associated with Avandia (rosiglitazone) that sparked...

Obesity expert Dr. Lee Kaplan of Massachusetts General Hospital tells us how we may be able to bypass the bypass…

Do insulin pumps always pump the same? Read on to learn more about the “siphon effect.”

Earlier this month, Eli Lilly and the German pharmaceutical Boehringer Ingelheim (BI) announced a major partnership to co-develop and co-commercialize several of their...

Kelly highlights an important diaTribe milestone and debriefs readers on the latest developments in diabetes technology.

A company that has long been in “stealth mode,” Cellnovo recently emerged with a new discreet insulin pump. Dubbed the Cellnovo 150/Cellnovo 50 (the Cellnovo 150 holds...

Sometimes, it might seem like the only way mobile phones improve your doctor visits is by giving you a chance to text your friends from the waiting room. That could be...

AADE spotlights self-management and patient-provider interactions.

Dexcom recently received CE Mark approval for its fourth-generation CGM sensor, clearing the new sensor for use in Europe. The company plans to first feature the sensor...

Pedometers – sensors that are worn to count the amount of steps taken throughout the day – have long been used to help measure physical activity and motivate people to...

All this talk about healthcare reform got us thinking...

After a day of deliberation earlier this month, a recent FDA advisory committee voted 13 to 7 to recommend approval of Contrave, a novel weight-loss drug made by...

Just in time for the New Year, Kelly reveals good news on obesity therapies and insulin delivery devices.

D. Medical's Spring Universal Infusion Set has been cleared by the FDA. After almost 18 months of review at the FDA, D. Medical’s subsidiary Spring-Set Health Solutions...

Just one day after the controversial meeting on Avandia, the FDA Advisory Committee met again, this time to consider the approval of a new weight loss drug named Qnexa,...

Decoding the evolving FDA perspective on diabetes devices (and how accurate is your meter, anyway?!).

A spotlight on new technologies for people with type 1 and type 2 diabetes at the Advanced Technologies and Treatments for Diabetes (ATTD) meeting.

Although the GLP-1 agonist drug class (like Byetta and Victoza ) and basal insulins (like Lantus and Levemir) have been around for some time, only recently have the two...